Published in Vaccine Weekly, November 10th, 2004
The company expects to report revenues of approximately $3.2 million and a net loss of approximately $24.0 million, or $0.54 per share, for the quarter ended September 30, 2004.
Cell Genesys also expects to report that it ended the quarter with approximately $152.6 million in cash, cash equivalents and short-term investments, including restricted cash and investments, and in addition held approximately 6.6 million shares of its former subsidiary, Abgenix, Inc.
Cell Genesys is focused on the development and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.